TriPath Imaging Ramps Up Regulatory And Clinical Spending In 2006
This article was originally published in The Gray Sheet
Executive Summary
TriPath Imaging will increase investment in its regulatory and clinical affairs programs by $6.5 mil.-$7 mil. in 2006 to support FDA approval of its breast cancer staging assay, SurePath molecular Pap test and FocalPoint GS imaging system